IDEXX Laboratories Announces Increase in Share Repurchase Program Authorization
09 December 2024 - 11:30PM
Business Wire
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet
healthcare innovation, today announced that the Company’s Board of
Directors authorized an increase in its ongoing share repurchase
program, authorizing the repurchase of up to five million
additional shares of the Company’s common stock. Repurchases may be
made at management’s discretion from time to time in the open
market (including through Rule 10b5-1 plans) or in negotiated
transactions. These shares are in addition to the 1.3 million
shares remaining under the Company’s ongoing share repurchase
program as of December 3, 2024, pursuant to previous Board
authorizations. The share repurchase program has no specified
expiration date and may be suspended or discontinued at any
time.
About IDEXX Laboratories, Inc.
IDEXX is a global leader in pet healthcare innovation. Our
diagnostic and software products and services create clarity in the
complex, constantly evolving world of veterinary medicine. We
support longer, fuller lives for pets by delivering insights and
solutions that help the veterinary community around the world make
confident decisions—to advance medical care, improve efficiency,
and build thriving practices. Our innovations also help ensure the
safety of milk and water across the world and maintain the health
and well-being of people and livestock. IDEXX Laboratories, Inc. is
a member of the S&P 500® Index. Headquartered in Maine, IDEXX
employs approximately 11,000 people and offers solutions and
products to customers in more than 175 countries and territories.
For more information about IDEXX, visit www.idexx.com.
Note Regarding Forward-Looking Statements
This news release contains or may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including statements about the Company’s
business prospects and estimates of the Company’s financial results
for future periods. Forward-looking statements can be identified by
the use of words such as “expects,” “may,” “anticipates,”
“intends,” “would,” “will,” “plans,” “believes,” “estimates,”
“should,” “project,” and similar words and expressions. These
forward-looking statements are intended to provide our current
expectations or forecasts of future events; are based on current
estimates, projections, beliefs, and assumptions; and are not
guarantees of future performance. Actual events or results may
differ materially from those described in the forward-looking
statements. These statements are subject to risks, uncertainties,
assumptions, and other important factors. Readers are cautioned not
to put undue reliance on such forward-looking statements because
actual results may vary materially from those expressed or implied.
The reports filed by IDEXX pursuant to United States securities
laws contain discussions of some of these risks and uncertainties.
IDEXX assumes no obligation to, and expressly disclaims any
obligation to, update or revise any forward-looking statements,
whether as a result of new information, future events, or
otherwise. Readers are advised to review IDEXX’s filings with the
United States Securities and Exchange Commission (which are
available from the SEC’s EDGAR database at sec.gov and via IDEXX’s
website at idexx.com).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241208581314/en/
Investor Relations investorrelations@idexx.com
IDEXX Laboratories (NASDAQ:IDXX)
Historical Stock Chart
From Nov 2024 to Dec 2024
IDEXX Laboratories (NASDAQ:IDXX)
Historical Stock Chart
From Dec 2023 to Dec 2024